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Abstract
Nefopam hydrochloride is a potent analgesic compound that possesses a profile distinct from that of opiods or anti-inflammatory
drugs. Previous evidence suggested a central action of nefopam but the detailed mechanisms remain unclear. Here we have used
cultured cerebellar neurons to test the hypothesis that nefopam may modulate voltage sensitive sodium channel (VSSC) activity.
Nefopam (100 µM) effectively prevented NMDA receptor-mediated early appearance (30 min) of toxicity signs induced by the
VSSC activator veratridine. Delayed neurotoxicity by veratridine occurring independently from NMDA receptor activation, was
also prevented by nefopam. In contrast, excitotoxicity following direct exposure of neurons to glutamate was not affected. Neuropro-
tection by nefopam was dose-dependent. 50% protection was obtained at 57 µM while full neuroprotection was achieved at 75 µM
nefopam. Veratridine-induced sodium influx was completely abolished in nefopam-treated neurons. Intracellular cGMP and oxygen
radical formation following VSSC stimulation by veratridine were also effectively prevented by nefopam. Our data are consistent
with an inhibitory action of nefopam on VSSC and suggest that nefopam may modulate the release of endogenous glutamate
following activation of these channels. This novel action of nefopam may be of great interest for the treatment of neurodegenerative
disorders involving excessive glutamate release and neurotransmission.  2001 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Nefopam hydrochloride is a potent analgesic com-
pound commercialized in most Western European coun-
tries for 20 years. Nefopam possesses a profile distinct
from that of opioids or anti-inflammatory drugs. It does
not cause tolerance, withdrawal reactions or physical
dependence, and the potential for its abuse is very low
(Heel et al., 1980). Furthermore, nefopam does not pro-
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duce respiratory depression even in the post-operative
period (Gasser and Bellville, 1975; Gerbershagen and
Schaffner, 1979). Clinical studies have demonstrated
nefopam to be very effective in the prevention of post-
operative shivering in patients after general anesthesia
(Rosa et al., 1995) without affecting the recovery time
between the end of anesthesia and extubation (Piper et
al., 1999). Unpleasant adverse effects during therapeutic
use have been also reported including dizziness, head-
ache, nausea, vomiting and sweating, consistent with a
central mode of action of the drug. Although these side
effects are usually minor and not very long lasting, they
can probably explain the limited development of
nefopam for post-operative use in the last years.
The analgesic properties of nefopam are now being
reinvestigated. This drug has been recently demonstrated
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to induce a rapid and strong depression of the nocicep-
tive flexion (RIII) reflex in humans (Guirimand et al.,
1999), probably through a central mechanism of action
(Hunskaar et al., 1987; Fasmer et al., 1987). However,
the detailed mechanisms underlying the pharmacological
actions of nefopam remain unclear. Evidence exists sug-
gesting a possible action of nefopam on the neuro-
transmission mediated by glutamate. Thus, nefopam is a
cyclic analogue of orphenadrine and diphenhydramine,
drugs originally synthesized as central myorelaxants
which exert unspecific antagonistic activity at the phen-
cyclidine binding site of NMDA receptors (Kornhuber
et al., 1995). Furthermore, nefopam shows pre-emptive
analgesic effects in a model of neuropathy (chronic con-
striction injury of the sciatic nerve) (Biella et al., unpub-
lished results) which involves the activation of NMDA
receptors. In this study, we have used primary cultures
of cerebellar neurons to test the hypothesis that nefopam
modulated glutamate neurotransmission via NMDA
receptors following depolarization of neurons by the
voltage sensitive sodium channel activator veratridine.
Cultured cerebellar neurons represent a neuronal model
that has proved very useful in the study of the biochemi-
cal events coupled to glutamate receptors and the con-
ditions controlling excitotoxicity (McCaslin and Mor-
gan, 1987; Nicoletti et al., 1986; Novelli et al. 1987,
1988, 1992). In these cultures, the capability of depolar-
izing stimuli such as veratridine to release glutamate has
been demonstrated (Gallo et al., 1982), and the amount
of glutamate released is capable of activating NMDA
receptors and promoting cGMP synthesis (Ferna´ndez-
Sa´nchez and Novelli, 1993), as well as excitotoxicity
(Dı´az-Trelles et al., 1999). We report that nefopam
effectively inhibits the influx of sodium following VSSC
activation by veratridine. We also show that nefopam
effectively prevents NMDA receptor-dependent and
independent neuronal death as well as cGMP and oxygen
radical formation following activation of voltage sensi-
tive sodium channels by veratridine. The novel action of
nefopam we report here may be of great interest for the
treatment of neurodegenerative disorders involving
excessive glutamate release and neurotransmission.
2. Methods
2.1. Cell cultures
Primary cultures of rat cerebellar neurons were pre-
pared as previously described (Novelli et al. 1988, 1992).
Briefly, cerebella from 8-day-old pups were dissected,
cells were dissociated and suspended in basal Eagle’s
medium with 25 mM KCl, 2 mM glutamine, 100 µg/ml
gentamycin and 10% fetal calf serum. Cells were seeded
in poly-L-Lysine coated (5 µg/ml) 35 mm dishes at
2.5×105 cells/cm2 and incubated at 37°C in a 5% CO2,
95% humidity, atmosphere. Cytosine arabinoside (10
µM) was added after 20–24 h of culture to inhibit the
replication of non-neuronal cells. After eight days in
vitro, morphologically identifiable granule cells
accounted for more than 95% of the neuronal population,
the remaining 5% being essentially GABAergic neurons.
Astrocytes did not exceed 3% of the overall number of
cells in culture. Cerebellar neurons were kept alive for
more than 40 days in culture by replenishing the growth
medium with glucose every four days and compensating
for lost amounts of water, due to evaporation.
2.2. Neurotoxicology
Neurons were used between 14–20 days in culture.
Drugs were added into the growth medium at the indi-
cated concentrations, and neuronal cultures were
observed for signs of early neurotoxicity at 30 min, as
well as for neuronal survival 24 h thereafter, by phase
contrast microscopy. To quantify neuronal survival, cul-
tures were stained with fluorescein diacetate and ethid-
ium bromide (Novelli et al., 1988; Ferna´ndez et al.,
1991), photographs of three randomly selected culture
fields were taken and live and dead neurons were coun-
ted. Results were expressed as percentage of live neu-
rons. Total number of neurons per dish was calculated
considering the ratio between the area of the dish and
the area of the picture (3000).
2.3. cGMP determination
Intracellular cGMP concentration was determined as
previously reported (Novelli and Henneberry, 1987).
Briefly, cultures were washed with 1 ml prewarmed
(37°C) incubation buffer containing (in mM): 154 NaCl,
5.6 KCl, 5.6 glucose, 8.6 HEPES, 1 MgCl2, 2.3 CaCl2,
pH 7.4. Dishes were incubated at 37°C for 10 min with
1 ml new incubation buffer and for an additional 20 min
with a second 1 ml new incubation buffer in which
MgCl2 was omitted. Drugs were added at the end of the
20 min incubation period for the indicated times. Incu-
bation was stopped by aspiration of the solution and
addition of 1 ml HClO4 (0.4 N). After neutralizing the
perchlorate extract, cGMP content was determined by
radioimmunoassay. Protein content was determined on
the membrane pellet from the same sample.
2.4. Confocal microscopy
Oxygen radical formation was detected with carboxy-
2’7’-dichlorodihydrofluoresceine diacetate (carboxy-
H2DCFDA). Following uptake, the carboxy-H2DCFDA
is converted by endogenous esterases to carboxy-
H2DCF, which upon exposure to oxidative species is
oxidized to the fluorescent probe carboxy-DCF. Neu-
ronal cultures were treated with the indicated drugs and
937M.T. Ferna´ndez-Sa´nchez et al. / Neuropharmacology 41 (2001) 935–942
loaded with 20 µM carboxy-H2DCFDA in the culture
medium for 1 h. Then, the dye was removed and cultures
were washed twice with a buffer containing (in mM):
154 NaCl, 5.6 KCl, 5.6 glucose, 8.6 HEPES, 1 MgCl2,
2.3 CaCl2, pH 7.4. Carboxy-DCF fluorescence was
recorded in a Bio–Rad confocal microscope with a kryp-
ton–argon laser excitation source (488 nm). Signals were
digitized using Bio–Rad interface and fluorescence
intensity was quantified in 10–15 cell bodies per field
using the software NIH Image (1.61).
Intracellular sodium was determined using Sodium
Green. A stock solution of Sodium Green tetraacetate (1
mM) and the nonionic detergent Pluronic F127 (20%
w/v) were prepared in dimethyl sulfoxide and mixed in
equal volumes just prior to cell loading. Neuronal cul-
tures were loaded for 20–30 min at 20°C with 3 µM
Sodium Green tetraacetate in an incubation buffer con-
taining (in mM): 154 NaCl, 5.6 KCl, 5.6 glucose, 8.6
HEPES, 1 MgCl2, 2.3 CaCl2, pH 7.4. The dye was
removed and cells were washed twice with the same
buffer. Sodium Green emission (532 nm) was recorded
in a Bio–Rad confocal microscope with a krypton–argon
laser excitation source (488 nm). Signals were digitized
using Bio–Rad interface and analysed by the software
NIH Image (1.61). As the increase in fluorescence inten-
sity affected mostly the neurites, for each treatment we
determined the average signal obtained from 8–10 fields
of the same size (41×62 pixels). Concentrations of intra-
cellular sodium ([Na+]I) could be estimated using the fol-
lowing equation:
[Na+]IKd(FFmin)/(FmaxF)
where F is the fluorescence of the indicator at experi-
mental sodium levels, Fmin is the fluorescence in the
absence of sodium and Fmax is the fluorescence of the
sodium-saturated probe. Mean values for Fmin and Fmax
were ascertained using cells that have been loaded with
Sodium Green tetraacetate and then treated with the
pore-forming antibiotic gramicidin (40 µM). To deter-
mine Fmin a Na+-free incubation buffer was used in
which NaCl was substituted by coline chloride. The dis-
sociation constant Kd of Sodium Green for Na+ is about
21 mM at 22°C. Although calculation of [Na+]I using
single-wavelength dyes is inherently less accurate than
using dual-wavelength ratioable indicators, published
comparisons show good quantitative agreement between
Sodium Green and the dual-wavelength dye SBFI
(Amorino and Fox, 1995).
2.5. Data presentation and analysis
For statistical analysis the one-way or the two-way
analysis of variance (ANOVA) was used to identify
overall treatment effects, followed by the unpaired two-
tailed Student’s t-test for selective comparison of indi-
vidual data groups. Only significances relevant for the
discussion of the data are indicated in each figure.
2.6. Materials
Carboxy 2’,7’-dichlorodihydrofluoresceine diacetate
(carboxy-H2DCFDA, C-400) and Sodium Green tetraa-
cetate (S-6901) were from Molecular Probes. Saxitoxin
was a generous gift of Dr. V. Zitko of St. Andrews Bio-
logical Station, N.B. (Canada). Nefopam, veratridine, L-
glutamate, nifedipine and (+)-10,11-dihydro-5-methyl-
5H-dibenzo-[a,d]-cyclohepten-5,10-imine hydrogen
maleate (MK-801) were from Sigma.
3. Results
Activation of voltage sensitive sodium channels
(VSSC) by veratridine (10 µM) resulted within 30 min
in swelling and darkening of cell bodies and appearance
of varicosities in neurites (Fig. 1B). These signs were
similar to those elicited by exposure of cultures to toxic
concentrations of exogenous glutamate (Novelli et al.,
1988), and they could be completely prevented by the
N-methyl-D-aspartate (NMDA) receptor antagonist MK-
801 (1 µM) (Fig. 1D). Exposure of cultures to nefopam
(100 µM) for 5 min before veratridine stimulation com-
pletely prevented the appearance of veratridine-induced
NMDA receptor-dependent excitotoxicity (Fig. 1F). It
has to be noted that nefopam did not reduce neurotoxic-
ity by exogenous glutamate (40 µM) (see Table 1),
although both veratridine and glutamate-induced signs
of excitotoxicity could be effectively blocked by MK-
801 (Fig. 1D and data not shown). Longer exposures to
veratridine (24 h) led to a significant reduction in neu-
ronal survival that occurred independently of the pres-
ence of MK-801 (Table 1 and Fig. 1C and E). A pro-
gressive shrinking of cell bodies could be observed in
neurons treated with veratridine in the presence of MK-
801, until a complete degeneration occurred (Fig. 1E).
In contrast, neurons pretreated with nefopam showed no
signs of toxicity after 24 h exposure to veratridine, and
appeared similar to controls (see Fig. 1G and A).
Nefopam effectively protected neurons from toxicity by
veratridine both in the absence and in the presence of
MK-801 (Table 1). To confirm the involvement of VSSC
in veratridine toxicity we used the VSSC blocker saxi-
toxin (Terlau et al., 1991) and nifedipine, a blocker of
L-type voltage sensitive calcium channels (Janis et al.,
1987) which effectively reduced neurotoxicity following
depolarization by KCl (Ferna´ndez et al., 1991). Veratrid-
ine toxicity was completely prevented by 50 nM saxi-
toxin while nifedipine (5 µM) was ineffective (Table 1).
Nefopam protection from veratridine-induced neuro-
toxicity was concentration dependent (Fig. 2). A slight
but statistically significant protective effect was
observed as low as 20 µM nefopam, 50% protection was
achieved at approximately 57 µM, and full neuroprotec-
tion required at least at 75 µM nefopam.
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Fig. 1. Nefopam protects neurons from NMDA receptor dependent and independent components of veratridine toxicity. Phase contrast images
represent neuronal cultures at 14 DIC untreated (A) or exposed to veratridine (VTD 10 µM) for 30 min (B,D,F) or 24 h (C,E,G), in the absence
(B,C) or in the presence of either 1 µM MK-801 (D,E) or 100 µM nefopam (F,G). MK-801 and nefopam were added 5 min prior to VTD. Similar
data was obtained at least five times using different neuronal cultures.
Table 1
Nefopam protects neurons from veratridine-induced neurotoxicitya
Neuronal survival (%)
None Nefopam
Control 94±4a 96±5
VTD 10±5 92±8d
VTD+MK-801 7±4 89±8d
VTD+STX 93±3b n.d.
VTD+NIF 8±7 n.d.
GLU 5±5 7±6
GLU+MK-801 90±9c n.d.
a Cerebellar neurons in primary culture were exposed to the indi-
cated drugs and neuronal survival was determined 24 h later. MK-801,
saxitoxin (STX) and nifedipine (NIF) were added 5 min before other
drugs. Concentrations were: Nefopam 100 µM; VTD 10 µM; STX 50
nM; MK-801 1 µM; NIF 10 µM; glutamate (GLU) 40 µM. Values
represent the mean±SD from three independent experiments (n=6).
b P0.01 vs. VTD in the same column.
c P0.01 vs. GLU in the same column.
d P0.01 vs. None in the same line.
Our results strongly suggest nefopam to inhibit
sodium influx via voltage sensitive sodium channels. To
test this possibility we did sodium imaging experiments
using the fluorescent dye Sodium Green, previously
shown to provide resolution of Na+ concentrations with
sufficient selectivity in the presence of physiological
concentrations of other monovalent cations (Minta and
Tsien, 1989; Amorino and Fox, 1995). In the absence of
nefopam, 20 µM veratridine significantly enhanced the
fluorescence intensity of Sodium Green (see Fig. 3), con-
sistent with an increase in the concentration of intracellu-
lar sodium following the application of veratridine.
Although a rise in fluorescence intensity could be
observed in both cell bodies and neurites, the most
prominent increase occurred in the neuritic network (Fig.
3B). In contrast, no increase in the fluorescence intensity
could be observed in cultures stimulated with 20 µM
veratridine in the presence of 100 µM nefopam (Fig. 3C
and D). Quantification of the fluorescence intensity sig-
nals (see Methods) showed that veratridine elicited a sig-
nificant mean increase from 9±2 to 17±3 fluorescence
units (f.u.) in the absence of nefopam, while no increase
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Fig. 2. Nefopam protection from veratridine-induced neurotoxicity is
concentration-dependent. Neuronal cultures at 14–18 DIC were treated
with increasing concentrations of nefopam added 5 min before veratri-
dine (10 µM). Neuronal survival was determined 24 h later. Data rep-
resent the mean±SD of two independent experiments (n=6). #P0.01
and *P0.001 vs. veratridine in the absence of nefopam.
in fluorescence intensity could be observed in nefopam-
treated neurons (Fig. 3E). Following the addition of ver-
atridine, the concentration of sodium was estimated (see
Methods) to rise from approximately 12±4 to 45±10 mM
(mean±SD, n=12), values similar to those reported by
other authors in cultured hippocampal neurons (Rose and
Ransom, 1997). In nefopam-treated neurons the concen-
trations of sodium were estimated to be 6±3 before and
2±2 mM after the application of veratridine respectively.
To investigate how neuroprotective concentrations of
nefopam would affect second messenger formation, we
determined the effect of nefopam on the intracellular for-
mation of cGMP following the activation of VSSC by
veratridine. As shown in Fig. 4, veratridine (10 µM)
resulted in an approximately 10 fold increase in intra-
cellular concentrations of cGMP, and such elevation
could be effectively prevented by the application of 100
µM nefopam 5 min before veratridine. cGMP formation
by the direct guanylate cyclase activator sodium
nitroprusside (1 mM) was not affected by nefopam.
We also assessed for the participation of oxidative
stress in veratridine-induced excitotoxicity. We used the
fluorescent probe carboxy-dichlorodihydrofluorescein
diacetate (carboxy-H2DCFDA), as dichlorodihydrofluo-
rescein diacetate and derivatives have proved extremely
useful for assessing the overall oxidative stress in toxico-
logical phenomena in a variety of experimental systems
including cultured neurons (Behl et al., 1994; Cubells et
al., 1994). As shown in Fig. 5, application of veratridine
Fig. 3. Nefopam prevents the increase in intracellular sodium induced
by veratridine. Neuronal cultures were loaded for 20–30 min at 20°C
with 3 µM Sodium Green tetraacetate and then examined under a laser
confocal microscope. (A–D) Representative images taken before (A,C)
or 30 s after (B,D) the addition of 20 µM veratridine (VTD) in the
absence (A,B) or in the presence (C,D) of 100 µM nefopam (NFM).
Scale colour bar spans from orange (minimum) to purple (maximum)
corresponding to fluorescence intensity values of 0 and 255 respect-
ively. (E). Images as the ones represented in (A–D) were used to esti-
mate intracellular sodium concentrations before (none) or after the
application of 20 µM veratridine in the absence (NFM) or in the
presence of nefopam (+NFM). As the increase in fluorescence intensity
affected mostly the neurites, for each treatment we report the concen-
tration calculated from the fluorescence intensity obtained from 8–10
fields of the same size (41×62 pixels). Results represent the mean±SD
of two independent experiments (n=6–10). °P0.05 vs. none in the
absence of NFM.
(20 µM) resulted after 2 h in a strong rise in fluorescence
intensity in most cell bodies and neurites (Fig. 5B) com-
pared to unstimulated cultures (Fig. 5A), consistent with
a significant increase in the generation of reactive oxy-
gen species. Radical formation was completely abolished
in neurons to which nefopam was added 5 min prior to
the application of veratridine (Fig. 4C). Quantification of
the fluorescence intensity revealed a veratridine-induced
increase from 67±7 to 174±42 f.u. in the absence of
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Fig. 4. Nefopam prevents depolarization-induced stimulation of
cGMP formation. Cerebellar neurons at 12–14 DIC were either
untreated (NONE) or exposed to nefopam (100 µM) for 5 min, before
stimulation of cultures with veratridine (VTD; 10 µM×1 min) or
sodium nitroprusside (SNP; 1 mM×2 min). cGMP content was determ-
ined by radioimmunoassay. Data are reported as the mean±SD of two
independent experiments performed in triplicate (n=6). *P0.001 vs.
unstimulated in the same group; #P0.001 vs. VTD in the absence
of nefopam.
Fig. 5. Nefopam prevents the formation of oxygen radicals induced
by veratridine. Neuronal cultures untreated (A) or exposed to veratrid-
ine (20 µM) either in the absence (B) or in the presence of 100 µM
nefopam (C), were loaded with 20 µM carboxy-H2DCFDA in the cul-
ture medium for 1 h. The carboxy-DCF fluorescence was recorded in
a Bio–Rad confocal microscope with a krypton–argon laser excitation
source (488 nm). Signals were digitized using Bio–Rad interface and
analyzed by NIH Image (1.61). Scale colour spans from black
(minimum) to white (maximum) corresponding to fluorescence inten-
sity values of 0 and 255 respectively. Nefopam was added 5 min before
veratridine and carboxy-H2DCFDA was added 1 h after veratridine.
The experiment was repeated three times with similar results. *P0.05
vs. none; #P0.05 vs. VTD.
nefopam, while no significant increase was observed in
the presence of 100 µM of this drug (78±16).
4. Discussion
Our results demonstrate the analgesic compound
nefopam to inhibit sodium influx, second messenger for-
mation, and neuronal death following the stimulation of
VSSC with veratridine. The capability of depolarizing
stimuli such as veratridine to release glutamate from cul-
tured cerebellar neurons has been demonstrated pre-
viously (Gallo et al., 1982), and the amount of glutamate
released is sufficient to activate NMDA receptors, to
stimulate cGMP synthesis (Ferna´ndez-Sa´nchez and Nov-
elli, 1993), and to induce excitotoxicity (see Fig. 1B).
Thus, our data provide novel evidence suggesting that
nefopam may modulate glutamatergic neurotransmis-
sion.
The early (30 min) MK-801-sensitive excitotoxic
component of veratridine toxicity was important in
determining the speed of the neurodegenerative process,
but it had a very minor contribution to the overall tox-
icity by veratridine after 24 h (see Fig. 1C and E). This
late, MK-801-independent toxicity, may be attributed to
the large influx of sodium through the persistently acti-
vated VSSC. Thus, our observation is consistent with
studies by other authors showing that NMDA receptor
antagonists failed to protect against toxicity after 24 h
exposure to veratridine (Ramnath et al., 1992; Dargent et
al., 1996; Takahashi et al., 1999), and confirms previous
results from our group (Dı´az-Trelles et al., 1999). The
failure of the NMDA receptor specific antagonist amino-
phosphonovalerate (APV) in reducing neuronal swelling
shortly after exposure to veratridine reported by other
authors (Ramnath et al., 1992) could be due to differ-
ences in the amount of glutamate released by different
neuronal types, or to the competitive characteristics of
APV.
It is tempting to speculate that the actions on VSSC
we report may play a significant role in the analgesic
effects of nefopam. Several lines of evidence suggest
sodium channel inhibition to be a mechanism for anal-
gesia (Besson, 1999). The sodium channel blocker car-
bamazepine has been shown to be effective in the treat-
ment of neuropathic pain (Rizzo, 1997; Harke et al.,
2001). Intrathecal administration of the sodium channel
blocker lamotrigine produced a spinal long-lasting anti-
hyperalgesic effect in short- and long-term neuropathic
models of hyperalgesia (Klamt, 1998). Also, an inhi-
bition of veratridine-induced sodium influx has been
found for antidepressants and neuroleptics used in
chronic pain (Deffois et al., 1996)
Evidence exists for a potential antagonistic action of
nefopam on NMDA receptors. The nefopam analogue
orphenadrine compete with MK-801 at the phencyclid-
ine binding site of the NMDA receptor (Kornhuber et
al., 1995). Nefopam strongly reduces behavioral and
electrophysiological signs of the neuropathy induced by
ligature of the sciatic nerve (Biella et al., unpublished
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results), and NMDA receptor activation appears to be
critical for the development and maintenance of the cen-
trally mediated events in the course of this neuropathy
(Kim et al., 1997; Kawata and Omote, 1996). Also, here
we show nefopam to effectively prevent the veratridine-
induced formation of oxygen radicals (Fig. 5), a key
event in the occurrence of NMDA receptor mediated
neurotoxicity (Coyle and Puttfarcken, 1993; Dı´az-Trelles
et al., 2000). However, our data suggest an inhibitory
action of nefopam on sodium channels rather than a
direct action of nefopam on NMDA receptors. Indeed,
nefopam failed to prevent neuronal death following the
direct activation of receptors by exogenous glutamate
(Table 1). Receptor binding studies using rat hyppo-
campus homogenates showed that nefopam significantly
displaced MK-801 only at concentrations of at least 1
mM (data not shown), also excluding a possible block
of NMDA receptors by nefopam. Instead, nefopam neur-
oprotection from the NMDA receptor-dependent excito-
toxic early component of veratridine toxicity, may be
associated to a reduction of the release of glutamate from
neurons in culture due to the inhibition of VSSC. The
inhibitory action of nefopam on VSSC is supported by
the observation that it significantly prevented the rise in
intracellular sodium induced by veratridine (Fig. 3), as
well as the late (24 h) NMDA-receptor independent
effects of veratridine (Fig. 1G and Table 1). Moreover,
veratridine was not toxic for neurons maintained in a
Na+-free incubation buffer in which NaCl was substi-
tuted by coline chloride (data not shown). Such an
inhibitory effect of nefopam would be also consistent
with the observation that it completely abolished the
increase in cGMP synthesis following depolarization of
neurons with veratridine (Fig. 4), as approximately 65%
of total veratridine-induced intracellular increase in
cGMP is NMDA receptor stimulation-independent
(Ferna´ndez-Sa´nchez and Novelli, 1993).
Several lines of evidence indicate sodium influx to be
the cause of neuronal death following activation of
VSSC with veratridine (Takahashi et al., 1999; Dargent
et al., 1996). Our results here further confirm this view
as both early and late veratridine toxicity could be totally
prevented by the specific VSSC blocker saxitoxin, while
the L-type voltage sensitive calcium channel antagonist
nifedipine was not effective (see Table 1). Other depola-
rizing stimuli capable of increasing intracellular calcium
concentrations failed to induce neurodegeneration in the
presence of MK-801 (Ferna´ndez et al., 1991; Novelli et
al., 1995). Therefore, veratridine neurotoxicity in the
presence of MK-801 cannot be due to the release of
endogenous amino acids activating other types of excit-
atory amino acid receptors, or to an excessive influx of
calcium via voltage sensitive calcium channels. Cultured
cerebellar neurons express GABA receptors (Gallo et al.,
1985), and GABAergic neurons account for approxi-
mately 3% of total neuronal population in these cultures
(Nicoletti et al., 1986). Therefore, it is possible to specu-
late that nefopam could mimic the action of GABA
receptor agonists and protect neurons by increasing
GABAergic inhibitory neurotransmission. However, the
GABA receptor agonist muscimol did not prevent vera-
tridine-induced toxicity (data not shown), rendering such
possibility unlikely.
In conclusion, this study demonstrates the analgesic
compound nefopam hydrochloride to reduce sodium
influx and to effectively prevent intracellular formation
of cGMP and oxygen radicals as well as neuronal death
following the activation of voltage-operated sodium
channels in cultured cerebellar neurons. This novel
action of nefopam may be of interest in reducing the
excessive release of endogenous glutamate involved in
some neurodegenerative disorders.
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